MedTrace Logo

Study for Detection of Donor-derived Cell-free DNA After Renal Transplantation Using Devysers NGS-based Chimerism Assay.

NCT05226936 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 50

Last updated 2022-02-07

No results posted yet for this study

Summary

The aim of this study is to evaluate highly sensitive quantitative tests for early molecular detection of graft rejection and associated immune response from liquid biopsies in the blood from patients undergoing renal transplantation and secondly, to evaluate the evolution of de-novo HLA antibodies following renal transplantation. Furthermore, we are interested in the correlation of tissue damage caused by rejection, as measured by the presence of dd-cfDNA, and the presence of de-novo HLA antibodies.

Conditions

  • Cell-Free Nucleic Acids

Interventions

DIAGNOSTIC_TEST

Cell free DNA analysis

samples will be analysed using molecular techniques including sequencing for measuring dd-cfDNA or analysis of the presence of HLA-antibodies using commercial bead-technologies (Luminex or Immucor)

Sponsors & Collaborators

  • Dan Hauzenberger M.D., Ph.D. Assoc. Professor, Karolinska University Hospital Sweden

    collaborator UNKNOWN

  • Sheba Medical Center

    lead OTHER_GOV

Eligibility

Min Age
20 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-04-01
Primary Completion
2024-03-31
Completion
2024-03-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05226936 on ClinicalTrials.gov